Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of SK08 live biotherapeutic powder for irritable bowel syndrome with diarrhea
CTR20233811Phase 3Active
- Sponsor
- Zhiyi Bio
- Start
- Mar 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SK08 in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Zhiyi Bio. Started Mar 2024; status: active.
02
Drugs
SK08
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on CTR20233811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233811.